Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JASON B FLEMING and JEAN NICOLAS VAUTHEY.
JASON B FLEMING
Connection Strength
1.853
JEAN NICOLAS VAUTHEY
  1. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013 Jul; 37(7):1695-700.
    View in: PubMed
    Score: 0.228
  2. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012 Nov; 16(11):2056-63.
    View in: PubMed
    Score: 0.107
  3. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012 Jul; 215(1):41-51; discussion 51-2.
    View in: PubMed
    Score: 0.105
  4. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.102
  5. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. HPB (Oxford). 2019 07; 21(7):841-848.
    View in: PubMed
    Score: 0.041
  6. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. J Surg Oncol. 2018 Jun; 117(8):1648-1654.
    View in: PubMed
    Score: 0.040
  7. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg. 2018 03; 267(3):552-560.
    View in: PubMed
    Score: 0.039
  8. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.038
  9. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13):3954-3963.
    View in: PubMed
    Score: 0.038
  10. Operative and short-term oncologic outcomes of laparoscopic versus open liver resection for colorectal liver metastases located in the posterosuperior liver: a propensity score matching analysis. Surg Endosc. 2018 04; 32(4):1776-1786.
    View in: PubMed
    Score: 0.038
  11. Tips and tricks of splenic vessel preservation during laparoscopic distal pancreatectomy. Surg Endosc. 2018 04; 32(4):2149-2150.
    View in: PubMed
    Score: 0.038
  12. Effective Laparoscopic Management Lymph Node Dissection for Gallbladder Cancer. Ann Surg Oncol. 2017 Jul; 24(7):1852.
    View in: PubMed
    Score: 0.037
  13. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.036
  14. Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis. J Gastrointest Surg. 2017 04; 21(4):636-646.
    View in: PubMed
    Score: 0.036
  15. Laparoscopic Partial Splenectomy for Unknown Primary Cancer: A Stepwise Approach. Ann Surg Oncol. 2017 Apr; 24(4):1134.
    View in: PubMed
    Score: 0.036
  16. Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. J Surg Oncol. 2017 Feb; 115(2):144-150.
    View in: PubMed
    Score: 0.036
  17. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.036
  18. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. J Gastrointest Surg. 2016 12; 20(12):1966-1974.
    View in: PubMed
    Score: 0.036
  19. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2017 01; 21(1):155-163.
    View in: PubMed
    Score: 0.036
  20. Laparoscopic Insulinoma Enucleation from the Retro-Pancreatic Neck: A Stepwise Approach. Ann Surg Oncol. 2016 06; 23(6):2001.
    View in: PubMed
    Score: 0.034
  21. After Pancreatectomy, the ?90 Days from Surgery? Definition Is Superior to the ?30 Days from Discharge? Definition for Capture of Clinically Relevant Readmissions. J Gastrointest Surg. 2016 Jan; 20(1):77-84; discussion 84.
    View in: PubMed
    Score: 0.034
  22. Spleen and splenic vessel preserving distal pancreatectomy for bifocal PNET in a young patient with MEN1. Surg Endosc. 2016 10; 30(10):4619.
    View in: PubMed
    Score: 0.034
  23. Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. Ann Surg. 2015 Dec; 262(6):1071-8.
    View in: PubMed
    Score: 0.034
  24. Advances in hepatectomy technique: Toward zero transfusions in the modern era of liver surgery. Surgery. 2016 Mar; 159(3):793-801.
    View in: PubMed
    Score: 0.034
  25. Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy. Ann Surg Oncol. 2015 Oct; 22(11):3522-9.
    View in: PubMed
    Score: 0.032
  26. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2015 Jul; 22(7):2416-23.
    View in: PubMed
    Score: 0.032
  27. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg. 2014 Jul; 219(1):111-20.
    View in: PubMed
    Score: 0.030
  28. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.029
  29. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.029
  30. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.029
  31. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.029
  32. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford). 2014 Apr; 16(4):373-83.
    View in: PubMed
    Score: 0.029
  33. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol. 2012 Dec; 19(13):4078-84.
    View in: PubMed
    Score: 0.027
  34. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.026
  35. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.026
  36. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford). 2012 Aug; 14(8):506-13.
    View in: PubMed
    Score: 0.026
  37. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.026
  38. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.026
  39. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.026
  40. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.025
  41. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37.
    View in: PubMed
    Score: 0.025
  42. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.025
  43. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.023
  44. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.021
  45. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063-72.
    View in: PubMed
    Score: 0.020
  46. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May; 206(5):833-46; discussion 846-8.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.